* If you want to update the article please login/register
"This study provides a rationale for the use of MDMA in the treatment of negative symptoms by reviewing the literature on negative symptoms, their treatment, MDMA, and MDMA-assisted therapy. It examines new evidence that supports the safe and potentially effective use of MDMA to treat negative symptoms and concludes with considerations regarding safety and potential mechanism of action. ".
Source link: https://doi.org/10.3390/jcm11123255
From inpatient and outpatient clinics, we recruited 54 first-episode schizophrenia patients, 52 BD patients, 35 MDD patients, and 54 healthy controls. Using the Brief Psychiatric Rating Scale and Positive and Negative Syndrome Scale, manic signs using the Young Mania Rating Scale, and depressive symptoms using the 17 item-Hamilton Depression Rating Scale, psychological signs were assessed. We also measured executive performance using the computerized Cambridge Neuropsychological Test Automated Battery, which was distributed to all participants. In differentiating patient groups from controls, Neurotensin outperformed all biomarkers. There were no significant differences between the three patient groups in their ability to distinguish between the three patient groups. In both FES and BD groups, lower oxytocin and higher substance p were associated with more psychotic signs. In both three patient groups, b3-endorphin was found to be a contributor to early morning wakening. Conclusion According to the study, circulating neuropeptides have the ability to distinguish severe mental disorders from controls.
Source link: https://doi.org/10.21203/rs.3.rs-1705849/v1
"Therefore, the aim of this research was to determine whether BDNF levels were related to depressive signs in patients with first-episode and drug-nau00efve schizophrenia. " 90 patients with FEDN schizophrenia and 60 healthy controls were recruited in this research. Compared to healthy controls, patients with FEDN schizophrenia had lower blood BDNF levels. In addition, patients with depressive illness had a higher PANSS total score and a higher general psychopathology score than those without depressive symptoms. serum BDNF levels were elevated in patients with depressive symptoms than those without depressive symptoms. In conclusion, BDNF levels were found to be higher in the serum of patients with FEDN schizophrenia with depressive symptoms in patients with depressive symptoms in comparison to those without. Low serum BDNF levels in addition to FEDN schizophrenia's positive signs may contribute to the FEDN schizophrenia's positive effects, but not to depressive symptoms.
Source link: https://doi.org/10.3389/fpsyt.2022.911384
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions